SUNDAY, MAY 20, 2018

ADMA Biologics receives patent for immunodeficiency treatment

Patent for immunodeficiency treatment issued to ADMA Biologics
Patent for immunodeficiency treatment issued to ADMA Biologics | Courtesy of
ADMA Biologics, Inc., a late-stage biopharmaceutical company, said Monday it has received a patient for its treatment of immunodeficiency.

The U.S. Patent and Trademark Office issued U.S. Patent 9,107,906 under the title “Compositions And Methods For The Treatment of Immunodeficiency.”

The patent is related to new treatment uses human plasma immunoglobulin compositions with antibody titers specifically for respiratory pathogen plurality. The patent also covers methods of recognizing human donors as well as donor samples for this treatment, ways of developing the compositions and ways to use the compositions for therapeutic or prophylactic treatments.

The new patent terms reach to January 2035.

"The issuance of ADMA's patent validates the differentiated, unique and novel way ADMA approaches immune globulin products,” ADMA Biologics President and CEO Adam Grossman, said. “ADMA's goal is to ensure adherence to all FDA standards and produce an IG product with consistent lot to lot potency of polyclonal antipathogen antibodies. This is a major milestone for our company as it provides us the ability to protect our lead product candidate and at the same time supports development of a wide range of other therapeutic IG products for patients with immunodeficiency and related diseases. The company will continue to aggressively pursue additional proprietary rights encompassing this technology."